Shrinking of a growth hormone-producing pituitary tumor by continuous subcutaneous infusion of the somatostatin analog SMS 201-995

SMS 201-995, a long-acting somatostatin analog, was given as the initial treatment to an acromegalic patient. SMS 201-995 (200 micrograms, sc, three times daily) reduced, but did not normalize, serum GH levels. Complete and prolonged control of GH secretion was obtained with a 600-micrograms daily c...

Full description

Saved in:

Bibliographic Details
Published in:	The journal of clinical endocrinology and metabolism Vol. 65; no. 5; p. 1042
Main Authors:	Ducasse, M C, Tauber, J P, Tourre, A, Bonafe, A, Babin, T, Tauber, M T, Harris, A G, Bayard, F
Format:	Journal Article
Language:	English
Published:	United States 01-11-1987
Subjects:	Adult Antineoplastic Agents - therapeutic use Female Growth Hormone - biosynthesis Growth Hormone - secretion Humans Infusion Pumps Injections, Subcutaneous Octreotide Pituitary Gland - drug effects Pituitary Gland - physiopathology Pituitary Neoplasms - drug therapy Pituitary Neoplasms - metabolism Pituitary Neoplasms - pathology Pituitary Neoplasms - secretion Somatostatin - administration & dosage Somatostatin - adverse effects Somatostatin - analogs & derivatives Somatostatin - therapeutic use Time Factors
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	SMS 201-995, a long-acting somatostatin analog, was given as the initial treatment to an acromegalic patient. SMS 201-995 (200 micrograms, sc, three times daily) reduced, but did not normalize, serum GH levels. Complete and prolonged control of GH secretion was obtained with a 600-micrograms daily continuous sc infusion (CSI), and the patient was treated in this way for 6 months. Rapid improvement of clinical signs and symptoms of acromegaly occurred, as did major tumor shrinkage. The other pituitary functions did not change. After 6 months, the daily SMS 201-995 dose was progressively reduced; GH secretion remained suppressed. After 12 months of treatment, GH secretion was controlled with a CSI of 100 micrograms SMS 201-995 daily, but not with two daily sc 100-micrograms injections. Further significant reduction in tumor size occurred. We conclude that CSI of SMS 201-995 resulted in constant GH normalization and marked clinical and morphological improvement. This form of treatment should be considered as an alternative to ablative treatment of acromegaly.
ISSN:	0021-972X
DOI:	10.1210/jcem-65-5-1042